Abstract:Prostate cancer (PCa) is a commonly diagnosed malignancy in men. The transcription factor p53, a well-known cancer suppressor, has been extensively analyzed in the progression of many tumor types, but its involvement in PCa remains not fully understood. Hence, this study aims to explore the possible molecular mechanism underlying p53 in the growth and metastasis of PCa. Based on bioinformatics analysis findings of GEPIA and starBase databases, p53 was demonstrated to be involved in the development of PCa by transcriptionally activating microRNA-519d-3p (miR-519d-3p) expression to suppress the expression of E2F transcription factor 1 (E2F1) and CD147. In order to verify this finding, clinically-obtained PCa tumor tissues were enrolled and commercially-purchased PCa cell lines were used to detect the cell viability, cycle, and apoptosis, as well as invasion and migration by CCK-8, flow cytometry, and Transwell assays respectively. The results of clinical tissue experiments and in vitro cell experiments showed that miR-519d-3p and p53 were poorly-expressed in PCa tissues and cell lines, while E2F1 was highly-expressed. Overexpression of miR-519d-3p led to inhibited PCa cell proliferation, invasion and migration, and p53 overexpression was found to promote miR-519d-3p expression to suppress the malignant characteristics of PCa cells, while the additional E2F1 overexpression restored the malignant traits. Moreover, ChIP analysis and dual-luciferase reporter assay confirmed the interactions among p53, miR-519d-3p, and E2F1. Mechanistically, it was found that p53 transcriptionally activated miR-519d-3p to suppress E2F1 expression. Finally, the in vitro results were further validated by in vivo experiments, which showed that miR-519d-3p prevents tumorigenesis and lymph node metastasis of PCa in nude mice via negatively regulation of E2F1 and CD147. Taken together, the findings uncover that the transcription factor p53 could upregulate miR-519d-3p expression to directly suppress the expression of E2F1, thus inhibiting PCa growth and metastasis. It highlights a novel therapeutic strategy against PCa based on the p53/miR-519d-3p/E2F1 regulatory pathway.

RNA Interference Targeting Mutant P53 Inhibits Growth and Induces Apoptosis in DU145 Human Prostate Cancer Cells

Silencing of Mutant P53 by Sirna Induces Cell Cycle Arrest and Apoptosis in Human Bladder Cancer Cells

[Effect of siRNA for mutant p53 gene on biological behavior of gastric cancer cell line SGC7901].

Data from Genetic Ablation of <i>rbm38</i> Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

MicroRNA-340 Inhibits Prostate Cancer Cell Proliferation and Metastasis by Targeting the MDM2-p53 Pathway.

Enhanced tumor suppression in vitro and in vivo by co-expression of survivin-specific siRNA and wild-type p53 protein

Sirna-Mediated Type 1 Insulin-Like Growth Factor Receptor Silencing Induces Chemosensitization of a Human Liver Cancer Cell Line with Mutant P53

Synergistic Suppression of Prostatic Cancer Cells by Coexpression of Both Murine Double Minute 2 Small Interfering RNA and Wild-Type p53 Gene In Vitro and In Vivo

Silencing of CD24 enhances the PRIMA-1-induced restoration of mutant p53 in prostate cancer cells.

Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities

Suppression of Bcl-xL Expression by a Novel Tumor-Specific RNA Interference System Inhibits Proliferation and Enhances Radiosensitivity in Prostatic Carcinoma Cells

Mutant P53 Gene Silencing Achieved in PLC/PRF/5 Cancer Cells by Using RNA Interference

Regulates P21, Bax, and Mdm2 to Inhibit Prostate Cancer Progression and Prolong Survival

Targeting mutant p53 for cancer therapy: direct and indirect strategies

PIM-1 Gene RNA Interference Induces Growth Inhibition and Apoptosis of Prostate Cancer Cells and Suppresses Tumor Progression in Vivo

Intracellular CD24 Disrupts the ARF–NPM Interaction and Enables Mutational and Viral Oncogene-Mediated P53 Inactivation

LIN28B inhibition sensitizes cells to p53-restoring PPI therapy through unleashed translational suppression

Targeting P53 for Novel Anticancer Therapy.

Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.

Transcription factor p53-mediated activation of miR-519d-3p and downregulation of E2F1 attenuates prostate cancer growth and metastasis